Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
Ironwood presented survey findings at DDW 2026 highlighting HCP prioritization of reducing TPN days and volume for SBS patients, alongside long-term safety data for its GLP-2 analog apraglutide. The LANDMARK survey of 336 HCPs found reducing TPN days per week is the top priority for future therapies, aligning with endpoints in the ongoing STARS and planned STARS-2 trials.
Key figures
- Hcp survey participants
- 336
- Estimated sbs if patients
- 18000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.